Physician profile
Berne B Bahnson
NPI 1871565499
$948.83
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $176.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $226.63 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $171.65 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $142.34 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $60.67 | 2019-2020 | |
| Lundbeck LLC | $58.19 | 2019-2020 | |
| Neos Therapeutics, LP | $55.77 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $39.37 | 2019 | |
| Merck Sharp & Dohme LLC | $39.06 | 2019 | |
| Sunovion Pharmaceuticals INC. | $37.86 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $34.53 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $33.63 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $12.79 | 2019 | |
| Allergan, INC. | $12.46 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.07 | 2019 | |
| Harmony Biosciences LLC | $11.81 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Berne Bahnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.